Skip to main content
. Author manuscript; available in PMC: 2019 Jan 2.
Published in final edited form as: Clin Oncol (Belmont). 2017 Jan 5;2:1183.

Figure 2. Hypothetical advanced targeted drug delivery system for Ewing sarcoma.

Figure 2

A. LINGO-1 is expressed on cell of the CNS protected by the BBB. The presence of a biomimetic corona around i-NPs prevents their crossing the BBB to avoid any potential CNS side effects. An additional advantage of using i-NP carrying anti-cancer drugs would be prolonged blood circulation half-life.

B. The anti-LINGO-1 i-NPs would only recognise EWS tumour cells with LINGO-1 for adhesion.

C. After binding, LINGO-1 cause’s receptor-mediated endocytosis followed by NP disruption of the endosome for release their drug contents.